|
IMPROVEMENT IN
HEALTH-RELATED QUALITY OF LIFE IN SLE PATIENTS ENROLLED IN A RANDOMIZED
CLINICAL TRIAL COMPARING LJP 394 WITH PLACEBO
Vibeke Strand, et al.
Presented at
The American College of Rheumatology
New Orleans, Louisiana
October 26, 2002
THE ORIENTATION OF b2-GLYCOPROTEIN I (b2-GPI) ON THE PLATE IS IMPORTANT
FOR THE BINDING OF ANTI-b2-GPI AUTOANTIBODIES BY ELISA
G. Michael Iverson, et al.
Presented at the
10th International Congress on APS
Sicily, Italy
September 29-October 3, 2002
A NOVEL THERAPEUTIC
APPROACH FOR TREATING ANTIPHOSPHOLIPID SYNDROME BASED ON TOLERIZING
ANTI-BETA2 GLYCOPROTEIN I B CELLS
Linnik MD, et al.
Presented at
FOCIS 2nd Annual Meeting
San Francisco, CA
June 28-July 1, 2002
DOMAIN 1-SPECIFIC
ANTI-b2GPI ANTIBODIES FROM APS PATIENTS CONTRIBUTE TO LUPUS ANTICOAGULANT
ACTIVITY
Patricia A. McNeeley, et al.
Presented at
the
1st Tutzing Antiphospholipid Conference
Bavaria, Germany
Apr. 22-25, 2002.
THE ORIENTATION OF
b2-GLYCOPROTEIN I (ß2GPI) ON THE PLATE IS IMPORTANT FOR
THE BINDING OF ANTI-ß2GPI AUTOANTIBODIES BY ELISA
G. Michael Iverson, et al.
Presented at
the
1st Tutzing Antiphospholipid Conference
Bavaria, Germany
Apr. 22-25, 2002.
TREATMENT OF ANTIBODY-MEDIATED
SLE-LIKE DISEASE IN MALE BXSB MICE WITH A B-CELL TOLERAGEN SPECIFIC
FOR ANTI-dsDNA ANTIBODIES
Douglas C. Saffran, et al.
Presented at the
Keystone Symposium: "Mechanisms & Applications of Immune
Tolerance"
Steamboat Springs, CO.
Apr. 3-9, 2002.
EFFECT OF LJP 394
OR HIGH DOSE CORTICOSTEROIDS AND CYCLOPHOSPHAMIDE ON ANTI-dsDNA
ANTIBODIES IN SLE PATIENTS
MD Linnik, et al.
Presented at the
Keystone Symposium: "Mechanisms & Applications of Immune
Tolerance"
Steamboat Springs, CO.
Apr. 3-9, 2002.
REDUCTION IN ANTIBODIES
TO dsDNA USING LJP 394 IN DOSE RANGING TRIAL IN LUPUS PATIENTS
MD Linnik, et al.
Presented at the 3rd International Congress
on Autoimmunity
Geneva, Switzerland
Feb. 20-24, 2002
EFFECT
OF LJP 394, HIGH DOSE CORTICOSTEROIDS
AND CYCLOPHOSPHAMIDE (HDCC) ON ANTI-dsDNA
ANTIBODIES IN SLE PATIENTS.
MD Linnik, et al.
Presented at the
3rd International Congress on Autoimmunity
Geneva, Switzerland
Feb. 20-24, 2002.
USE
OF MUTATIONS IN DOMAIN 1 AND DOMAIN
4 OF ß2GPI TO DETERMINE FINE ANTIGENIC
SPECIFICITY OF ANTIPHOSPHOLIPID AUTOANTIBODIES
G. Michael Iverson, et al.
Presented at the
3rd International Congress on Autoimmunity
Geneva, Switzerland
Feb. 20-24, 2002.
|
HEPARIN INHIBITS THE BINDING OF BETA 2-GLYCOPROTEIN I TO PHOSPHOLIPIDS
AND PROMOTES THE PLASMIN-MEDIATED INACTIVATION OF THIS BLOOD PROTEIN.
ELUCIDATION OF THE CONSEQUENCES OF THE TWO BIOLOGICAL EVENTS IN
PATIENTS WITH THE ANTII-PHOSPHOLIPID SYNDROME
Guerin J, et
al.
Published in the
Journal of Biological Chemistry
2002 Volume 277:pp 2644-2649
THE ORIENTATION OF
B2GPI ON THE PLATE IS IMPORTANT FOR THE BINDING OF ANTI-B2GPI
AUTOANTIBODIES BY ELISA
Iverson GM, et al.
Published in
Journal of Autoimmunity, 2002
Volume 18: 289-297
USE OF SINGLE POINT
MUTATIONS IN DOMAIN I OF BETA2-GLYCOPROTEIN I TO DETERMINE FINE
ANTIGENIC SPECIFICITY OF ANTIPHOSPHOLIPID AUTOANTIBODIES
GM Iverson, et al.
Published in
The Journal of Immunology
2002, Vol 169, Iss 12, pp 7097-7103
WORKSHOP
REPORT ON SOME NEW IDEAS ABOUT THE TREATMENT
OF SYSTEMIC LUPUS ERYTHEMATOSUS
Linnik M, et al.
Published in Lupus,
2002. Volume 11, Issue 12. pp793-6
ANTI-BETA(2)-GLYCOPROTEIN
I ANTIBODY-MEDIATED INHIBITION OF ACTIVATED
PROTEIN C REQUIRES BINDING OF BETA(2)-GLYCOPROTEIN
I TO PHOSPHOLIPIDS
T Izumi,et al.
Published in
Thrombosis and Haemostasis, 2002, Vol
88,
Issue 4, pp 620-626
|